Major Recall: Pfizer’s Pills Risk Poisoning Children

A whopping four million Nurtec ODT packages have been hastily recalled by Pfizer due to worries about potential child poisoning risks. The United States Consumer Product Safety Commission (CPSC) has swiftly announced the recall as a result of this worrying development.

A well-known migraine drug is urgently recalled by Pfizer because of packaging that may be dangerous to children because it lacks child-resistant characteristics. Such packaging must, according to the CPSC, be extremely challenging for children under the age of five to open.

JUST IN: Trump 24K Golden Dollars – Available Now!

As advised by the safety committee, Pfizer is providing free child-resistant pouches to Nurtec ODT customers, bringing convenience and safety to a whole new level.

“The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children,” the CPSC said.

With an unshakable commitment to the Poison Prevention Safety Act (PPPA), Pfizer takes prompt action by recalling a staggering 4.2 million packets of Nurtec ODT, each containing eight 75 mg dissolving tablets. This life-saving drug must be stored in child-resistant packaging.

“The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, NDC number and expiration date,” said the safety commission.

It was a major time for pharmaceutical sales since pharmacies all around the nation supplied drug packages from December 2021 to March 2023.

Customers are assured by Nurtec that there is no need to return their items, and it is made clear that a “recall” may entail a number of different measures, including product repair, replacement, refund, or notice/warning.

Have You Seen This? The TRB Black Card is Something That Every Single Patriot Is Passionately Waiting For!

The astonishing successes of Paxlovid and Comirnaty propelled Pfizer’s revenues to a record-breaking $100.3 billion in 2022, marking an exciting breakthrough.